Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleNuclear Oncology

Nonmyeloablative Iodine-131 Anti-B1 Radioimmunotherapy as Outpatient Therapy

Vanessa L. Gates, James E. Carey, Jeffry A. Siegel, Mark S. Kaminski and Richard L. Wahl
Journal of Nuclear Medicine July 1998, 39 (7) 1230-1236;
Vanessa L. Gates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James E. Carey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffry A. Siegel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark S. Kaminski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard L. Wahl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 39, Issue 7
July 1, 1998
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nonmyeloablative Iodine-131 Anti-B1 Radioimmunotherapy as Outpatient Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Nonmyeloablative Iodine-131 Anti-B1 Radioimmunotherapy as Outpatient Therapy
Vanessa L. Gates, James E. Carey, Jeffry A. Siegel, Mark S. Kaminski, Richard L. Wahl
Journal of Nuclear Medicine Jul 1998, 39 (7) 1230-1236;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nonmyeloablative Iodine-131 Anti-B1 Radioimmunotherapy as Outpatient Therapy
Vanessa L. Gates, James E. Carey, Jeffry A. Siegel, Mark S. Kaminski, Richard L. Wahl
Journal of Nuclear Medicine Jul 1998, 39 (7) 1230-1236;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence
  • Tositumomab and 131I Therapy in Non-Hodgkin's Lymphoma
  • Radiation Dosimetry Results and Safety Correlations from 90Y-Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma: Combined Data from 4 Clinical Trials
  • Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma
  • A Practical Methodology for Patient Release After Tositumomab and 131I-Tositumomab Therapy
  • Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas
  • Outpatient Treatment with 131I-Anti-B1 Antibody: Radiation Exposure to Family Members
  • Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
  • Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma
  • Google Scholar

More in this TOC Section

  • PET Evaluation of Therapeutic Limb Perfusion in Merkel's Cell Carcinoma
  • Response to Treatment with Yttrium 90-DOTA-Lanreotide of a Patient with Metastatic Gastrinoma
  • Flare Response Seen in Therapy for Osteomalacia
Show more Nuclear Oncology

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire